SciSparc Receives Final Approval for Phase IIb Clinical Trial of SCI110 for Tourette Syndrome

SciSparc has just received the final green light to kick off its Phase IIb clinical trial for SCI-110, an innovative drug candidate aimed at treating Tourette Syndrome. The clinical trial will evaluate the safety, efficacy, and tolerability of SCI-110 in adult patients between 18 and 65, who will be treated with the drug orally daily. During the trial, patients will be randomly assigned to receive either SCI-110 or a placebo that matches SCI-110.

The Israeli Ministry of Health has permitted the clinical trial at the Tel Aviv Sourasky Medical Center in Tel Aviv, Israel. SciSparc is a clinical-stage pharmaceutical company specializing in developing treatments for central nervous system disorders, including neurological and psychiatric conditions. SCI-110 is a cannabinoid-based treatment that SciSparc is developing to treat various neurological and psychiatric disorders.

In July 2021, SciSparc updated its Phase IIb study on Tourette Syndrome, stating that it was scheduled to begin in the latter half of 2021. The recent approval of the clinical trial indicates that the investigation is on track to meet this timeline. Suppose the Phase IIb clinical trial is successful. In that case, SciSparc will be one step closer to receiving regulatory approval for SCI-110 as a treatment for Tourette Syndrome.

SPRC Stock: Stable Performance but Lack of Information and Financial Performance Raises Concerns

On April 4, 2023, SPRC stock opened at 0.46, slightly higher than its previous close of 0.45. Throughout the day, the stock fluctuated within a range of 0.43 to 0.49. The trading volume for the day was 67,093, significantly lower than the average volume of 787,216 over the past three months.

SPRC is a company in the health technology sector, specifically in the pharmaceuticals: primary industry. Unfortunately, no information is available on the company’s market cap, revenue growth, P/E ratio, price/sales, price/book, net profit margin, or next reporting date. Additionally, there are no competitor’s data available for comparison.

The company’s earnings growth over the past year was -2,912.05%, a significant decline. However, no information is available on the company’s earnings growth for this year or the next five years. The lack of data on the company’s earnings growth and financial performance makes it difficult to predict the future performance of SPRC stock.

Regarding financials, SPRC reported annual revenue of $0.00 and an annual profit of -$5.8M. The lack of income and negative profit margin may cause investors to concern.

Overall, the performance of SPRC stock on April 4, 2023, was relatively stable, with a slight increase in the opening price. However, the company’s lack of information and financial performance may make it difficult for investors to make informed decisions about investing in SPRC stock.

Scisparc Ltd (SPRC) Stock Soars with 4,432.06% Increase in Median Target Price, Analysts Recommend Buy Rating

On April 4, 2023, Scisparc Ltd (SPRC) had a median target price of $20.00, according to one analyst who offered a 12-month price forecast. This represented a staggering increase of +4,432.06% from the last price of $0.44. The high and low estimates were also $20.00, indicating a solid consensus among analysts.

The current consensus among one polled investment analyst is to buy stock in Scisparc Ltd, a rating that has held steady since January. This suggests that the company has been performing well and is expected to continue.

Unfortunately, no information is available on the current quarter’s earnings per share or sales, as the reporting date is yet to be determined. However, given the positive outlook from analysts, it is reasonable to assume that the company’s financial performance is strong.

Overall, the stock performance of Scisparc Ltd on April 4, 2023, was impressive, with a median target price of $20.00 and a consensus buy rating from analysts. Investors may want to monitor the company’s financial results in the coming months to see if they continue to meet expectations.

Read more here: Source link

Leave a Reply

Your email address will not be published. Required fields are marked *